HSCS
HeartSciences Inc.
There isn't enough reported data to score HSCS yet.
HSCS Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
HSCS's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
HSCS PE Valuation
HSCS has no meaningful PE right now: it lost money over the past year.
HSCS Forward outlook
There aren't enough analyst estimates for HSCS to show an outlook.
HSCS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.76 | +$5.52 |
| Q2 2026 | -$3.48 | +$5.86 |
| Q1 2024 | -$46.00 | +$84.03 |
| Q4 2023 | -$59.00 | +$92.30 |
| Q3 2023 | -$65.00 | +$95.53 |
| Q2 2023 | -$80.00 | +$67.67 |
| Q1 2023 | -$130.03 | -$20.69 |
HSCS is still losing money, but far less than before: $2.76 per share over the past year, against $160.53 at its worst in mid-2022.
HSCS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.1K | +11% |
| Q1 2024 | $14.7K | +654% |
| Q1 2023 | $2K | -29% |
| Q3 2022 | $3.2K | -57% |
| Q2 2022 | $4.1K | -72% |
HSCS's revenue is recovering but still below its 2021 peak: $2,100 last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -139957% | -41319 points |
| Q4 2025 | -85713% | N/A |
| Q3 2025 | -98638% | N/A |
| Q1 2024 | -10377% | +56767 points |
| Q4 2023 | -40255% | N/A |
| Q1 2023 | -67144% | -26987 points |
| Q3 2022 | -44691% | -35679 points |
| Q2 2022 | -47670% | -42410 points |
HSCS's operating margin was −139957% last quarter, down 99702 points from the same quarter a year ago, near the bottom of its range since 2021.
HSCS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.3M | +$634.5K |
| Q2 2026 | -$1.7M | -$85.9K |
| Q1 2026 | -$1.5M | +$167K |
| Q3 2025 | -$2M | +$65.4K |
| Q2 2025 | -$1.6M | -$5.5K |
| Q1 2025 | -$1.6M | +$530.1K |
| Q3 2024 | -$2M | -$609.5K |
| Q2 2024 | -$1.6M | +$284.1K |
HSCS has burned cash in almost every quarter: −$6M over the past year, against −$7M the year before.
HSCS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +16% | +507K shares |
| 1 year | +272% | +2.7M shares |
| 3 years | +6399% | +3.6M shares |
HSCS has 4M diluted shares, up 272% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
HSCS Net Leverage
HSCS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HSCS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 26.7 | Neutral |
HSCS's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
HSCS PE vs Healthcare Sector
HSCS has no meaningful PE right now: it lost money over the past year.
HSCS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.35 | 33% below |
| 20 week MA | $3.09 | 27% below |
| 50 week MA | $2.73 | 17% below |
| 100 week MA | $3.07 | 26% below |
| 200 week MA | $24.3 | 91% below |
HSCS is in a downtrend: it's below all five of its weekly moving averages, and 91% below its 200-week average.
HSCS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $208.0 | $89.0 | -57% |
| 2023 | $89.0 | $17.1 | -81% |
| 2024 | $17.1 | $3.81 | -78% |
| 2025 | $3.81 | $2.85 | -25% |
| 2026 YTD | $2.85 | $2.26 | -21% |
HSCS has finished every year since 2022 lower, and it's down 21% so far in 2026.